News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


ImmunoCellular Therapeutics Announces Asset Purchase Agreement with Private Biotechnology Company


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 This is great news.   ICT-107 is an off the shelf vaccine for GBM.  The early clinical trials looked very good, but the final clinical trial "failed" and they stopped development of it.  However, there were quite a few responses and long term survivors from that trial.  There were probably some mistakes made in that trial design.  Patients that had certain biomarkers did well enough (adding over a year  to median time to progression compared to those without the biomarker)  get FDA approval but patients without those biomarkers had no benefit. Hopefully this new company will run the correct trial and make this vaccine available.  This is literally a shot in the arm (or leg) with the same side effects profile as the flu shot, and there are a few long term survivors out over 7 years who are not only alive, but in good shape, happy and still working.


Posted on: 07/17/2019

ImmunoCellular Therapeutics Announces Asset Purchase Agreement with Private Biotechnology Company

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740